South Korea Genitourinary Drugs Market Insight
Published: 29 July 2026 | Report Format: Electronic (PDF) | Author: Aditi and Govind
The South Korean genitourinary medication market is expected to grow at compound annual growth rate (CAGR) of 5.89% from 2025-2035 because to rising incidence of urological malignancies and benign prostatic hyperplasia.
South Korea Genitourinary Drugs Market Insights Forecasts to 2035
- The South Korea Genitourinary Drugs Market Size Was Estimated USD 982.6 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.89% from 2025 to 2035
- The South Korea Genitourinary Drugs Market Size is Expected to rise around USD 1740.7 Million by 2035
Notable Insights for the South Korea Genitourinary Drugs Market
- According to indication segmentation, bladder cancer, erectile dysfunction, and kidney cancer continue to rise steadily, whereas prostate cancer and urinary tract infections predominate.
- According to product segmentation, the market is dominated by urologicals and hormonal therapy, followed by anti-infectives and gynecological medications that cater to a variety of patient demands.
- Demand is driven by South Korea's aging population because BPH affects more than 50% of males in the 60-69 age range and more than 90% of those over 85, leading to higher diagnostic rates.
- With a favorable growth tendency of 3.94%, South Korea's genitourinary medication sales reached 235.7 million USD in 2023, demonstrating significant market momentum.
Download the eBook (ToC)
Research Methodologies Used to Analyze the South Korea Genitourinary Drugs Market
The market for drugs related to the system in South Korea is studied using a mix of primary and secondary research methods to get correct information about the market and reliable predictions. Secondary research means looking at reports from companies, government papers, health databases, medical magazines, studies done on patients, groups that help the drug industry data about prescriptions and other reports about the market. Advanced methods, for guessing how big the market is looking at trends and predicting what will happen are used to check how big the market is, where there are chances to grow, how medicines cost, new treatments that are being developed and what kind of investments might happen in the genitourinary drugs industry.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors do a lot of research to understand what is happening in the market. They look closely at what's going on in each industry. They also compare companies to see how they are doing. They try to figure out what will happen in the future with trends and they use data to help businesses make decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea genitourinary drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Genitourinary Drugs Market
- DongKoo Bio & Pharma Co., Ltd.
- JW Pharmaceutical (JWì¤‘ì™¸ì œì•½)
- Hanmi Pharmaceutical
- Shinpoong Pharmaceutical
- Dong-A ST
- Myungmoon Pharm Co., Ltd.
- Withus Pharmaceutical Co., Ltd.
- Hanmi Pharm
- Alvogen Korea
- HK inno.N
Recent Developments:
- In March 2025 DongKoo Bio & Pharma expanded its pharmaceutical offerings and made more treatment options available, for benign prostatic hyperplasia by launching a new urology therapy formulation.
- In February 2025 Dong-A ST boosted its pharmaceutical pipeline in South Korea by working with biotechnology companies to speed up the research and development of new genitourinary treatments.
Market Segmentation:
South Korea Genitourinary Drugs Market, By Indication
- Prostate Cancer
- Ovarian Cancer
- Bladder Cancer
- Cervical Cancer
- Renal Cancer
- Erectile Dysfunction
- Urinary Tract Infections
South Korea Genitourinary Drugs Market, By Product
- Urologicals
- Hormonal Therapy
- Gynecological
- Anti-infectives
- Others
South Korea Genitourinary Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Expert Views:
The market for genitourinary drugs in South Korea is poised for consistent growth owing to an aging population, high prevalence of diseases in the urological field, and constant advancement in the drug market. Increased availability of more sophisticated drugs increased clinical studies, and favorable health care system will improve the effectiveness of treatment. Investment in specialty drugs will ensure competitive edge and industry growth.
Author: Aditi and Govind By Decisions Advisors and Consulting